Intellia Therapeutics, Inc.

NTLA

Intellia Therapeutics, Inc.

NTLA

Insider Sentiment (TTM):

Last Purchase:2026-01-05Last Sale:2026-03-02Shares Purchased (TTM):250,000Shares Sold (TTM):175,703

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:108,424,242Shares Outstanding:118,490,000Institutional Ownership Pct.:91.50%

Earnings Market Reaction:

Filing Date:2026-05-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in In Vitro & In Vivo Diagnostic Substances

IDXX LNTH NEOG QDEL MYGN ACHV

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	135	155	193	156	127	189	120	131	172	227	168	172
Marketable Securities Current	241	294	318	303	377	412	538	560	619	685	687	736
Accounts Receivable Net Current	9	9	11	11	11	9	9	12	36	36	6	5
Prepaid Expense And Other Assets Current	81	68	60	25	37	30	44	54	56	50	32	26
Assets Current	466	528	582	496	551	640	711	757	884	998	893	940
Marketable Securities Noncurrent	141	155	159	171	203	260	287	249	162	100	138	164
Property Plant And Equipment Net	16	18	20	23	25	27	29	30	32	33	34	33
Operating Lease Right Of Use Asset	98	106	118	129	138	219	100	105	110	115	119	124
Equity Method Investments	-	-	-	-	-	0	0	0	0	12	17	22
Investments And Other Noncurrent Assets	38	36	46	80	68	44	47	50	71	43	42	41
Assets	759	842	925	899	986	1,191	1,173	1,192	1,260	1,301	1,243	1,323
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	19	20	13	10	12	15	13	19	14	7	4	12
Accrued Liabilities Current	38	50	41	42	41	55	51	45	43	67	58	50
Operating Lease Liability Current	19	26	27	27	39	20	19	19	19	19	17	17
Contract With Customer Liability Current	1	7	12	17	21	21	22	22	22	22	13	22
Liabilities Current	76	104	94	95	113	111	106	105	98	115	92	100
Contract With Customer Liability Noncurrent	-	0	13	13	13	18	23	28	33	39	13	13
Operating Lease Liability Noncurrent	61	67	71	76	80	190	82	87	92	97	101	106
Business Combination Contingent Consideration Liab…	-	-	-	-	-	-	-	-	-	0	0	0
Liabilities	138	171	177	184	206	319	211	220	223	251	206	-
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	3,307	3,260	3,242	3,108	3,071	3,049	3,008	2,885	2,803	2,711	2,567	2,513
Accumulated Other Comprehensive Income Loss Net Of…	-0	1	1	1	1	1	3	-1	-1	-2	-4	-4
Retained Earnings Accumulated Deficit	-2,686	-2,590	-2,494	-2,393	-2,292	-2,177	-2,049	-1,913	-1,766	-1,658	-1,526	-1,404
Stockholders Equity	621	671	748	715	780	872	963	971	1,036	1,050	1,037	1,105
Liabilities And Stockholders Equity	759	842	925	899	986	1,191	1,173	1,192	1,260	1,301	1,243	1,323
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	240	240	240	240	240	240	240	240	240	240	240	240
Common Stock Shares Issued	120	116	116	105	104	102	102	98	96	93	89	88
Shares Outstanding	120	116	116	105	104	102	102	98	96	93	89	88

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-6.10%	21.78%	-	-	-	-	-	-	-	-	-	-
2025	-17.03%	15.46%	64.19%	-0.92%	42.32%	123.39%	-27.03%	-23.38%	18.75%	-10.08%	4.69%	-4.27%
2024	-14.00%	-9.98%	6.60%	0.27%	-6.17%	-28.73%	-2.38%	-25.19%	-31.31%	-17.13%	-33.43%	-21.73%
2023	-	-	-	-2.15%	-17.14%	-31.85%	23.56%	22.16%	-1.12%	4.12%	-10.71%	-10.01%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	6.10	5.08	6.21	5.19	4.90	5.77	6.73	7.21	9.03	8.67	9.72	9.41
Quick Ratio	5.04	4.42	5.57	4.93	4.57	5.50	6.31	6.69	8.45	8.23	9.37	9.14
Working Capital	390.00M	423.83M	488.22M	400.45M	438.80M	529.01M	605.22M	652.12M	786.13M	883.12M	801.54M	839.76M
Leverage & Debt
Debt to Equity	0.22	0.25	0.24	0.26	0.26	0.37	0.22	0.23	0.22	0.24	0.20	0.09
Debt Ratio	0.18	0.20	0.19	0.20	0.21	0.27	0.18	0.19	0.18	0.19	0.17	0.08
Efficiency & Turnover
Asset Turnover TTM	0.08	0.07	0.05	0.05	0.04	0.05	0.04	0.04	0.04	0.03	0.04	0.04
Days Sales Outstanding TTM	54.22	48.50	63.14	81.77	187.95	141.81	65.00	69.02	143.40	202.37	37.07	27.22
Receivables Turnover TTM	6.73	7.53	5.78	4.46	1.94	2.57	5.62	5.29	2.55	1.80	9.85	13.41
Per Share Metrics
Diluted EPS TTM	-3.33	-3.81	-4.05	-4.63	-5.08	-5.25	-5.17	-5.25	-5.08	-5.42	-5.22	-5.14
Free Cash Flow Per Share TTM	-3.07	-3.65	-3.74	-4.07	-3.68	-3.59	-3.59	-3.95	-4.38	-4.60	-4.59	-4.36
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-636.56%	-651.67%	-832.16%	-968.69%	-1,187.36%	-923.10%	-1,247.99%	-1,140.05%	-983.45%	-1,420.51%	-937.87%	-867.11%
Net Profit Margin TTM	-597.04%	-609.85%	-774.94%	-908.48%	-1,154.10%	-896.77%	-1,212.19%	-1,106.87%	-922.94%	-1,326.51%	-893.34%	-854.92%
Growth Metrics
Net Revenue Growth (1Y)	45.04%	16.92%	33.52%	14.99%	-13.37%	59.55%	-16.77%	-13.33%	-1.63%	-30.40%	0.71%	16.98%
Net Income Growth (1Y)	-24.97%	-20.49%	-14.64%	-5.62%	8.32%	7.86%	12.94%	12.21%	12.79%	1.48%	4.62%	13.24%
EPS Growth (1Y)	-34.46%	-27.48%	-21.76%	-11.77%	-0.05%	-3.14%	-0.88%	2.04%	3.66%	-12.01%	-10.25%	-2.64%
Valuation Metrics
P/E TTM	-3.85	-2.36	-4.27	-2.03	-1.40	-2.22	-3.97	-4.27	-5.41	-5.62	-6.06	-7.93
P/B TTM	2.45	1.45	2.54	1.36	0.94	1.32	2.16	2.23	2.54	2.58	2.70	3.25
P/S TTM	22.98	14.40	33.08	18.41	16.15	19.91	48.17	47.21	49.94	74.61	54.15	67.80
Market Cap	1.52B	974.30M	1.90B	973.01M	735.89M	1.15B	2.08B	2.17B	2.63B	2.71B	2.80B	3.60B
Enterprise Value	1.38B	818.84M	1.71B	816.83M	609.01M	963.40M	1.96B	2.04B	2.46B	2.48B	2.63B	3.42B
Calculated Values
Free Cash Flow TTM	-363.63M	-395.87M	-412.63M	-421.82M	-381.16M	-354.66M	-363.06M	-382.65M	-418.08M	-408.07M	-407.28M	-384.33M
Net Debt	-134.70M	-155.46M	-193.39M	-156.17M	-126.88M	-189.18M	-120.50M	-130.85M	-171.98M	-226.75M	-168.03M	-171.81M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-02Sale

Owner: Clark, Eliana

Title: EVP, Chief Technical Officer

Shares: 607

Price/Share: $13.78

Value: $8,364.46

Shares Owned: 93,864

Relationship: Officer

Ownership: Direct

2026-03-02Sale

Owner: Basta, James

Title: EVP, General Counsel

Shares: 1,211

Price/Share: $13.78

Value: $16,687.58

Shares Owned: 156,794

Relationship: Officer

Ownership: Direct

2026-01-05Sale

Owner: Lebwohl, David

Title: EVP, Chief Medical Officer

Shares: 11,903

Price/Share: $9.21

Value: $109,626.63

Shares Owned: 121,249

Relationship: Officer

Ownership: Direct

2026-01-05Sale

Owner: Schultes, Birgit C

Title: EVP, Chief Scientific Officer

Shares: 8,508

Price/Share: $9.21

Value: $78,358.68

Shares Owned: 98,533

Relationship: Officer

Ownership: Direct

2026-01-05Sale

Owner: Dulac, Edward J Iii

Title: EVP, Chief Financial Officer

Shares: 6,379

Price/Share: $9.21

Value: $58,750.59

Shares Owned: 99,683

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-02	Clark, Eliana	Officer	EVP, Chief Technical Officer	Direct	Sale	607	13.78	$8,364.46	93,864	4
2026-03-02	Basta, James	Officer	EVP, General Counsel	Direct	Sale	1,211	13.78	$16,687.58	156,794	4
2026-01-05	Lebwohl, David	Officer	EVP, Chief Medical Officer	Direct	Sale	11,903	9.21	$109,626.63	121,249	4
2026-01-05	Schultes, Birgit C	Officer	EVP, Chief Scientific Officer	Direct	Sale	8,508	9.21	$78,358.68	98,533	4
2026-01-05	Dulac, Edward J Iii	Officer	EVP, Chief Financial Officer	Direct	Sale	6,379	9.21	$58,750.59	99,683	4
2026-01-05	Clark, Eliana	Officer	EVP, Chief Technical Officer	Direct	Sale	9,515	9.21	$87,633.15	87,118	4
2026-01-05	Cohen, Fred E	Director	-	Direct	Purchase	150,000	9.35	$1,402,500.00	207,453	4
2026-01-05	Dube, Michael P	Officer	VP, Chief Accounting Officer	Direct	Sale	2,989	9.21	$27,528.69	52,277	4
2026-01-05	Leonard, John M	Director,Officer	President and CEO	Direct	Sale	34,146	9.21	$314,484.66	1,013,339	4
2026-01-05	Basta, James	Officer	EVP, General Counsel	Direct	Sale	10,397	9.21	$95,756.37	101,528	4
2025-12-11	Leonard, John M	Director,Officer	President and CEO	Direct	Sale	88,146	9.52	$839,149.92	1,038,928	4
2025-10-01	Dube, Michael P	Officer	VP, Chief Accounting Officer	Direct	Sale	1,871	17.38	$32,517.98	55,266	4
2025-10-01	Schultes, Birgit C	Officer	EVP, Chief Scientific Officer	Direct	Sale	31	17.38	$538.78	105,184	4
2025-08-20	Chase, William J	Director	-	Direct	Purchase	100,000	10.03	$1,003,000.00	134,693	4
2025-07-23	Dulac, Edward J Iii	Officer	EVP, Chief Financial Officer	Direct	Sale	7,462	14.02	$104,617.24	106,062	4
2025-07-02	Dube, Michael P	Officer	VP, Chief Accounting Officer	Direct	Sale	2,503	9.95	$24,904.85	57,137	4
2025-07-01	Clark, Eliana	Officer	EVP, Chief Technical Officer	Direct	Sale	1,022	9.82	$10,036.04	95,369	4
2025-07-01	Goodman, Jesse	Director	-	Direct	Sale	1,547	9.23	$14,278.81	24,359	4
2025-04-29	Bhanji, Muna	Director	-	Direct	Sale	265	8.50	$2,252.50	19,203	4
2025-03-04	Basta, James	Officer	EVP, General Counsel	Direct	Sale	2,572	8.99	$23,122.28	111,925	4
2025-03-04	Clark, Eliana	Officer	EVP, Chief Technical Officer	Direct	Sale	679	8.99	$6,104.21	95,369	4
2025-01-29	Bhanji, Muna	Director	-	Direct	Sale	265	9.97	$2,642.05	19,468	4
2025-01-03	Leonard, John M	Director,Officer	President and CEO	Direct	Sale	26,807	12.18	$326,509.26	941,115	4
2025-01-03	Basta, James	Officer	EVP, General Counsel	Direct	Sale	7,074	12.18	$86,161.32	74,497	4
2025-01-03	Clark, Eliana	Officer	EVP, Chief Technical Officer	Direct	Sale	7,422	12.18	$90,399.96	64,048	4
2025-01-03	Dube, Michael P	Officer	VP, Chief Accounting Officer	Direct	Sale	1,372	12.18	$16,710.96	45,640	4
2025-01-03	Hicks, Derek	Officer	EVP, Chief Business Officer	Direct	Sale	6,502	12.18	$79,194.36	59,878	4
2025-01-03	Lebwohl, David	Officer	EVP, Chief Medical Officer	Direct	Sale	9,557	12.18	$116,404.26	87,666	4
2025-01-03	Sepp-Lorenzino, Laura	Officer	EVP, Chief Scientific Officer	Direct	Sale	8,966	12.18	$109,205.88	77,388	4
2024-10-02	Dube, Michael P	Officer	VP, Chief Accounting Officer	Direct	Sale	2,012	19.01	$38,248.12	47,012	4
2024-07-01	Clark, Eliana	Officer	EVP, Chief Technical Officer	Direct	Sale	405	22.93	$9,286.65	71,470	4
2024-06-17	Verwiel, Frank	Director	-	Direct	Sale	1,505	25.00	$37,625.00	17,948	4
2024-03-04	Clark, Eliana	Officer	EVP, Chief Technical Officer	Direct	Sale	605	32.99	$19,958.95	71,470	4
2024-03-04	Basta, James	Officer	EVP, General Counsel	Direct	Sale	2,297	32.99	$75,778.03	81,571	4
2024-01-08	Sepp-Lorenzino, Laura	Officer	EVP, Chief Scientific Officer	Direct	Sale	2,275	29.02	$66,020.50	43,927	4
2024-01-03	Leonard, John M	Director,Officer	President and CEO	Direct	Sale	19,223	29.46	$566,309.58	846,486	4
2024-01-03	Lebwohl, David	Officer	EVP, Chief Medical Officer	Direct	Sale	5,843	29.46	$172,134.78	54,372	4
2024-01-03	Basta, James	Officer	EVP, General Counsel	Direct	Sale	3,805	29.46	$112,095.30	51,474	4
2024-01-03	Clark, Eliana	Officer	EVP, Chief Technical Officer	Direct	Sale	4,608	29.79	$137,272.32	40,845	4
2024-01-03	Goddard, Glenn	Officer	EVP, Chief Financial Officer	Direct	Sale	5,365	29.46	$158,052.90	40,585	4
2024-01-03	Sepp-Lorenzino, Laura	Officer	EVP, Chief Scientific Officer	Direct	Sale	5,532	29.46	$162,972.72	46,202	4
2024-01-03	Hicks, Derek	Officer	EVP, Chief Business Officer	Direct	Sale	3,877	29.46	$114,216.42	36,987	4
2023-10-31	Bhanji, Muna	Director	-	Direct	Sale	265	23.90	$6,333.50	11,996	4
2023-07-31	Bhanji, Muna	Director	-	Direct	Sale	265	42.33	$11,217.45	12,261	4
2023-07-06	Bhanji, Muna	Director	-	Direct	Sale	1,867	39.30	$73,373.10	12,526	4
2023-07-03	Clark, Eliana	Officer	EVP, Chief Technical Officer	Direct	Sale	360	40.51	$14,583.60	45,146	4
2023-06-20	Clark, Eliana	Officer	EVP, Chief Technical Officer	Direct	Sale	5,000	45.00	$225,000.00	45,146	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

91.50%

Inst. Shares: 108,424,242

Shares Outstanding: 118,490,000

2025-12-31

94.55%

Inst. Shares: 102,470,639

Shares Outstanding: 108,376,000

2025-09-30

93.91%

Inst. Shares: 103,477,341

Shares Outstanding: 110,188,000

2025-06-30

94.24%

Inst. Shares: 97,755,981

Shares Outstanding: 103,732,000

2025-03-31

96.36%

Inst. Shares: 99,730,787

Shares Outstanding: 103,500,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	108,424,242	118,490,000	91.50%
2025-12-31	102,470,639	108,376,000	94.55%
2025-09-30	103,477,341	110,188,000	93.91%
2025-06-30	97,755,981	103,732,000	94.24%
2025-03-31	99,730,787	103,500,000	96.36%
2024-12-31	97,791,793	98,849,000	98.93%
2024-09-30	89,415,531	101,002,000	88.53%
2024-06-30	85,869,622	96,975,000	88.55%
2024-03-31	86,692,299	95,502,000	90.78%
2023-12-31	82,170,796	88,770,000	92.57%
2023-09-30	76,764,939	88,645,000	86.60%
2023-06-30	74,101,151	88,185,000	84.03%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Intellia Therapeutics, Inc. (NTLA) — SEC Financial Statements & Analysis

Intellia Therapeutics, Inc. (NTLA) is a in vitro & in vivo diagnostic substances company, incorporated in DE. Intellia Therapeutics, Inc. trades on NTLA: Nasdaq as: NTLA. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Intellia Therapeutics, Inc. reported a 45.04% year-over-year revenue growth, a Debt-to-Equity ratio of 0.22x, a Price-to-Sales (P/S) ratio of 22.98x (TTM), a Price-to-Book (P/B) ratio of 2.45 (TTM), at a market cap of $1.52B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 45.04%
Debt To Equity: 0.22x
P/S TTM: 22.98x
P/B TTM: 2.45
Market Cap: $1.52B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Intellia Therapeutics, Inc. in?

Intellia Therapeutics, Inc. (NTLA) operates in the In Vitro & In Vivo Diagnostic Substances industry.

What is NTLA's market cap?

Intellia Therapeutics, Inc. (NTLA) has a market capitalization of $1.52B as of 2026-03-31.

What exchange does NTLA trade on?

Intellia Therapeutics, Inc. (NTLA) trades on the NTLA: Nasdaq.

Where is Intellia Therapeutics, Inc. incorporated?

Intellia Therapeutics, Inc. is incorporated in DE.

Intellia Therapeutics, Inc. (NTLA) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.